Breast cancer therapy-associated cardiovascular disease

Nature Reviews Clinical Oncology

Volumn 13, Issue 3, 2016, Pages 172-184

  Zagar, Timothy M ^a   Cardinale, Daniela M ^b   Marks, Lawrence B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CAPECITABINE; CARVEDILOL; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAPATINIB; LETROZOLE; NEBIVOLOL; PACLITAXEL; PLACEBO; TAMOXIFEN; TELMISARTAN; TRASTUZUMAB; VALSARTAN; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT;

ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BREAST CANCER; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY SPASM; CORONARY BLOOD VESSEL; HEART ATRIUM ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; NONHUMAN; PERICARDITIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; REVIEW; RISK REDUCTION; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS; ADVERSE EFFECTS; ANIMAL; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; FEMALE; PRIMARY PREVENTION; PROCEDURES; RADIATION INJURIES; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; PRIMARY PREVENTION; RADIATION INJURIES; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84959105007     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.171     Document Type: Review

References (105)

1. Lee, M. S, Finch, W. & Mahmud, E. Cardiovascular complications of radiotherapy. Am. J. Cardiol. 112, 1688-1696 (2013).
2. Darby S. C. et al. Radiation-related heart disease: current knowledge and future prospects. Int. J. Radiat. Oncol. Biol. Phys. 76, 656-665 (2010).
3. Cuzick, J. et al. Overview of randomized trials of postoperative adjuvant radiation therapy in breast cancer. Cancer Treat. Rep. 71, 15-29 (1987).
4. Cuzick, J. et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol. 12,447-453 (1994).
5. Host, H., Brennhovd, I. O. & Loeb, M. Postoperative radiotherapy in breast cancer - long-term results from the Oslo study. Int. J. Radiat. Oncol. Biol. Phys. 12, 727-732 (1986).
6. Haybittle, J. L., Brinkley, D., Houghton, J., A'Hern, R. P. & Baum, M. Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer. BMJ 298, 1611-1614 (1989).
7. Rutqvist, L. E., Lax, I., Fornander, T., A'Hern, R. P. & Baum, M. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 22, 887-896 (1992).
8. Rutqvist, L. E. & Johansson, H. Mortality by laterality of the primary tumor among 55,000 breast cancer patients from the Swedish Cancer Registry. Br. J. Cancer 61, 866-868 (1990).
9. Hojris, I., Overgaard, M., Christensen, J. J. & Overgaard, J. Morbidity and mortality of ischemic heart disease in high-risk breast cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomized trials. Lancet 354, 1425-1430 (1999).
10. Harris, E. E. et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast conservation treatment. J. Clin. Oncol. 24, 4100-4106 (2006).
11. Paszat, L. F. et al. A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. Radiother. Oncol. 82, 294-300 (2007).
12. Correa, C. R. et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J. Clin. Oncol. 25, 3031-3037 (2007).
13. Hooning, M. J. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J. Natl Cancer Inst. 99, 365-375 (2007).
14. Borger, J. H. et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int. J. Radiat. Oncol. Biol. Phys. 69, 1131-1138 (2007).
15. Cvancarova, M. et al. Risk of death from cardiovascular disease in long-term breast cancer survivors: a comparison with women from the general population [abstract]. J. Clin. Oncol. 32, S5 a1534 (2014).
16. Clarke, M. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366, 2087-2106 (2005).
17. Janjan, N. A. et al. Dose to the cardiac vascular and conduction systems in primary breast irradiation. Med. Dosim. 14, 81-87 (1989).
18. Nieder, C., Schill, S., Kneschaurek, P. & Molls, M. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat. Oncol. 2, 20 (2007).
19. Taylor, C. W., Nisbet, A., McGale, P. & Darby, S. C. Cardiac exposures in breast cancer radiotherapy: 1950's-1990's. Int. J. Radiat. Oncol. Biol. Phys. 69, 1484-1495 (2007).
20. Taylor, C. W. et al. Cardiac dose from contemporary tangential breast cancer radiotherapy in the year 2006. Int. J. Radiat. Oncol. Biol. Phys. 72, 501-507 (2008).
21. Nilsson, G. et al. Distribution of coronary artery stenosis after radiation for breast cancer. J. Clin. Oncol. 30, 380-386 (2012).
22. Darby, S. C. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368, 987-998 (2013).
23. Marks, L. B. et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int. J. Radiat. Oncol. Biol. Phys. 63, 214-223 (2005).
24. Bell, L.. J. Cox, J., Eade, T. & Rinks, M. & Kneebone, A. The impact of rectal and bladder variability on target coverage during post-prostatectomy intensity modulated radiotherapy. Radiother. Oncol. 110, 245-250 (2014).
25. de Crevoisier, R. et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int. J. Radiat. Biol. Oncol. Phys. 62, 965-973 (2005).
26. Heemsbergen, W. D. et al. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68Gy versus 78 Gy. Int. J. Radiat. Oncol. Biol. Phys. 67, 1418-1424 (2007).
27. Michalski, J. M. et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int. J. Radiat. Oncol. Biol. Phys. 46, 391-402 (2000).
28. Gyenes, G., Fornander, T., Carlens, P., Glas, U. & Rutqvist, L. E. Myocardial damage in breast cancer patients treated with adjuvant radiotherapy: a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 36, 899-905 (1996).
29. Prosnitz, R. G. et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 110, 1840-1850 (2007).
30. Ishii, J. et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am. J. Cardiol. 89, 691-695 (2002).
31. Perna, E. R. et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 110, 2376-2382 (2004).
32. Nellessen, U. et al. Serial analysis of troponin I levels in patients with ischemic and nonischemic dilated cardiomyopathy. Clin. Cardiol. 29,219-224 (2006).
33. Nellessen, U., Zingel, M., Hecker, H., Bahnsen, J. & Borschke, D. Effects of radiation therapy on myocardial cell integrity and pump function: which role for cardiac biomarkers? Chemotherapy 56, 147-152 (2010).
34. Hughes-Davies, L., Sacks, D., Rescigno, J., Howard, S. & Harris, J. Serum cardiac troponin T levels during treatment of early-stage breast cancer. J. Clin. Oncol. 13, 2582-2584 (1995).
35. Kozak, K. R. et al. Cardiac blood biomarkers in patients receiving thoracic (chemo)radiation. Lung Cancer 62, 351-355 (2008).
36. Cardinale, D., Salvatici, M. & Sandri, M. T. Role of biomarkers in cardioncology. Clin. Chem. Lab. Med. 49, 1937-1948 (2011).
37. Christenson, E. S., James, T., Agrawal, V. & Park, B. H. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin. Biochem. 48, 223-235 (2015).
38. Hancock, S. L., Tucker, M. A. & Hoppe, R. T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. J. Am. Med. Assoc. 270, 1949-1955 (1993).
39. Bradley, J. D. et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 16, 187-199 (2015).
40. Hardy, D., Liu, C. C., Cormier, J. N., Xia, R. & Du, X. L. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann. Oncol. 21, 1825-1833 (2010).
41. Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998).
42. Grundy, S. M., Pasternak, R., Greenland, P., Smith, S. Jr & Fuster, V. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J. Am. Coll. Cardiol. 34, 1348-1359 (1999).
43. Ridker, P. M., Buring, J. E., Rifai, N. & Cook, N. R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds score. J. Am. Med. Assoc. 297, 611-619 (2007).
44. Paszat, L. F., Mackillop, W. J., Groome, P. A., Schulze, K. & Holowaty, E. Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: A population-based study in Ontario, Canada. Int. J. Radiat. Oncol. Biol. Phys. 43, 755-761 (1999).
45. Hooning, M. J. et al. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int. J. Radiat. Oncol. Biol. Phys. 64, 1081-1091 (2007).
46. Brenner, D. J., Shuryak, I., Jozsef, G., Dewyngaert, K. J. & Formenti, S. C. Risk and risk reduction of major coronary events associated with contemporary breast radiotherapy. JAMA Intern. Med. 174, 158-160 (2014).
47. Suter, T. M. & Ewer, M. S. Cancer drugs and the heart: importance and management. Eur. Heart J. 34, 1102-1111 (2013).
48. Lenihan D. J. & Cardinale, D. Late cardiac effects of cancer treatment. J. Clin. Oncol. 30, 3657-3664 (2012).
49. Jessup, M. et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 53, 1343-1382 (2009).
50. Hahn, V. S., Lenihan, D. J. & Ky, B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J. Am. Heart Assoc. 3, e000665 (2014).
51. Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642 (2012).
52. Yeh, E. T. & Bickford, C. L. Cardiovascular complications of cancer therapy. Incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53, 2231-2247 (2009).
53. Jones, L. W., Haykowsky, M. J., Swartz, J. J., Douglas, P. S. & Mackey, J. R. Early breast cancer therapy and cardiovascular injury. J. Am. Coll. Cardiol. 50, 1435-1441 (2007).
54. Von Hoff, D. D. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710-717 (1979).
55. Bowles, E. J. et al. Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl Cancer Inst. 104, 1293-1305, (2012).
56. Carver, J. R., Szalda, D. & Ky, B. Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin. Oncol. 40, 229-238 (2013).
57. Crone, S. A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459-465 (2002).
58. Lee, K. F. et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development Nature 378, 394-398 (1995).
59. Harbeck, N., Ewer, M. S., De Laurentiis, M., Suter, T. M. & Ewer, S. M. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann. Oncol. 22, 1250-1258 (2011).
60. Ewer, S. M. & Ewer, M. S. Carditoxicity profile of trastuzumab. Drug Saf. 31, 459-467 (2008).
61. Halyard, M. Y. et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J. Clin. Oncol. 27, 2638-2644 (2009).
62. Shapiro, C. L. et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J. Clin. Oncol. 16, 3493-3501 (1998).
63. Valagussa, P. et al. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann. Oncol. 5, 209-216 (1994).
64. Cardinale, D., Bacchiani, G., Beggiato, M., Colombo, A. & Cipolla. C. M. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin. Oncol. 40, 186-198 (2013).
65. Thavendiranathan, P. et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol. 63, 2751-2768 (2014).
66. Tamene, A. M., Masri, C. & Konety, S. H. Cardiovascular MR imaging in cardio-oncology. Magn. Reson. Imaging Clin. N. Am. 23, 105-116 (2015).
67. Cardinale, D. et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 55, 213-220 (2010).
68. Curigliano, G. et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann. Oncol. 23, S55-S66 (2012).
69. Telli, M. L., Hunt, S. A., Carlson, R. W. & Guardino, A. E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol. 25, 3525-3533 (2007).
70. Tocchetti. et al. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur. J. Heart Fail. 14, 130-137 (2012).
71. Mackey, J. R. et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr. Oncol. 15, 24-35 (2008).
72. Sengupta, P. P., Northfelt, D. W., Gentile, F., Zamorano, J. L. & Khandheria, B. K. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin. Proc. 83, 197-203 (2008).
73. Jones, A. L. et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br. J. Cancer 100, 684-692 (2009).
74. Martin, M. et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 14, 1-11 (2009).
75. Fyles, A. W. et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N. Engl. J. Med. 351, 963-970 (2004).
76. Hughes, K. S. et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J. Clin. Oncol. 31, 2382-2387 (2013).
77. Fisher, B. et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin. Oncol. 28, 400-418 (2001).
78. Houghton, J. et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362, 95-102 (2003).
79. Bijker, N. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J. Clin. Oncol. 24, 3381-3387 (2006).
80. Holmberg, L. et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J. Clin. Oncol. 26,1247-1252 (2008).
81. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
82. Dragun, A. E. et al. Increasing mastectomy rates among all age groups for early stage breast cancer: a 10-year study of surgical choice. Breast J. 18, 318-325 (2012).
83. Fisher, C. S. et al. Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann. Surg. Oncol. 19, 3246-3250 (2012).
84. Mahmood, U. et al. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann. Surg. Oncol. 20, 1436-1443 (2013).
85. Wang, X. et al. Cardiac motion during deep-inspiration breath-hold: implications for breast cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 82, 708-714 (2012).
86. Bruzzaniti, V. et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J. Exp. Clin. Cancer Res. 32, 88 (2013).
87. Tang, X. et al. Clinical experience with 3-dimensional surface matching-based deep inspiration breath hold for left-sided breast cancer radiation therapy. Pract. Radiat. Oncol. 4, e151-e158 (2014).
88. Zagar, T. M. et al. Prospective assessment of deep inspiration breath hold to prevent radiation associated cardiac perfusion defects in patients with left-sided breast cancer [abstract 2027]. Presented at the ASTRO Annual meeting, San Antonio, TX (2015).
89. Zellars, R. et al. SPECT analysis of cardiac perfusion changes after whole-breast/chest wall radiation therapy with or without active breathing coordinator: results of a randomized phase 3 trial. Int. J. Radiat. Oncol. Biol. Phys. 15, 778-785 (2014).
90. Formenti, S. C., DeWyngaert, J. K., Jozsef, G. & Goldberg, J. D. Prone vs supine positioning for breast cancer radiotherapy. JAMA 308, 861-863 (2012).
91. Chino, J. P. & Marks, L. B. Prone positioning causes the heart to be displaced anteriorly within the thorax: implications for breast cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 70, 916-920 (2008).
92. Würschmidt, F., Stoltenberg, S., Kretschmer, M. & Petersen, C. Incidental dose to coronary arteries is higher in prone than in supine whole breast irradiation. A dosimetric comparison in adjuvant radiotherapy of early stage breast cancer. Strahlenther Onkol. 190, 563-568 (2014).
93. Mulliez, T. et al. Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation. Radiother. Oncol. 114, 79-84 (2015).
94. Kalay, N. et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 48, 2258-2262 (2006).
95. Kaya, M. G. et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int. J. Cardiol. 167, 2306-2310 (2013).
96. Seicean, S. et al. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ. Heart Fail. 6, 420-426 (2013).
97. Nakamae, H. et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104, 2492-2498 (2005).
98. Cadeddu, C. et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am. Heart J. 160, e1-e7 (2010).
99. Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474-2481 (2006).
100. Bosch, X. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 61,2355-2362 (2013).
101. Kalam, K. & Marwick, T. H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur. J. Cancer 49, 2900-2909 (2013).
102. Seicean, S., Seicean, A., Plana, J. C., Budd, G. T. & Marwick, T. H. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J. Am. Coll. Cardiol. 60, 2384-2390 (2012).
103. Acar, Z. et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 58, 988-989 (2011).
104. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01968200 (2015).
105. Truong, J., Yan, A. T., Cramarossa, G. & Chan, K. K. Chemotherapy-induced cardiotoxicity: detection, prevention and management. Can. J. Cardiol. 30, 869-878 (2014).